Core Insights - Bio-Rad Laboratories, Inc. is well-positioned in the growing digital PCR market with its QX600 Droplet Digital PCR platform, while its clinical diagnostics business is gaining momentum and expanding into new molecular diagnostics areas [1][4] - The company has faced challenges in its Biopharma segment and margin performance due to economic pressures [1][12] Group 1: Company Performance - Bio-Rad's shares have decreased by 4.8% over the past year, contrasting with the industry's growth of 24.7% and the S&P 500's rise of 33.7% [2] - The company has a market capitalization of $893.9 million and has surpassed earnings estimates in three of the last four quarters, with an average surprise of 4.1% [2] Group 2: Key Drivers - The QX600 Droplet ddPCR platform is robust and growing, with a focus on biopharma and new product development in cell biology [4] - Bio-Rad is advancing its strategy through agreements with Allegheny Health Network and Oncocyte Corporation, enhancing its clinical diagnostic applications [5] - The clinical diagnostics segment is experiencing growth, particularly in the diabetes franchise and immunohematology, with new product launches like the IH-500 instrument [6][7] Group 3: International Expansion - Bio-Rad operates in over 35 countries, with optimism about market conditions improving in late 2024 and into 2025 despite current softness in the APAC region [8][9] Group 4: Challenges - The Biopharma segment has shown weakness since 2023, linked to funding constraints in the pharmaceutical industry, impacting sales in Asia [10][11] - Economic factors such as inflation and increased costs have pressured Bio-Rad's margins, with a noted unfavorable product mix affecting gross margins [12] Group 5: Financial Estimates - The Zacks Consensus Estimate for Bio-Rad's 2024 earnings per share remains at $10.31, while revenue estimates are projected at $2.59 billion, indicating a 3% decline from the previous year [13]

Core Insights - Bio-Techne Corporation will showcase its neuroscience research solutions at the Society for Neuroscience annual meeting from October 5-9, 2024, in Chicago, Illinois [1][5] - The company will present a range of high-quality life science reagents, immunoassays, automated proteomic instruments, and multiomics solutions aimed at enhancing research efficiency [2][5] Product Highlights - At booth 1165, Bio-Techne will feature technologies that streamline biomarker discovery, optimize neural cell cultures, and transform drug discovery processes [2] - The company will discuss a study on senescence in the aging brain using the RNAscope™ Multiomic LS assay for high-throughput spatial analysis [3] - A Product Theater presentation will focus on intracellular signaling in Alzheimer's disease, utilizing Simple Western™ technology for protein characterization [4] Presentations and Posters - Bio-Techne will host several presentations, including a discussion on intracellular signaling in Alzheimer's disease and a study on senescence in the aging brain [6][7] - The company will present posters on various topics, including an automated assay for quantifying pTau217 and visualizing neurexin and neuroligin interactions [6][7] Company Overview - Bio-Techne Corporation is a global life sciences company with approximately $1.2 billion in net sales for fiscal 2024 and around 3,100 employees [7]

VANCOUVER, British Columbia and HOLMDEL, N.J., Sept. 23, 2024 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (NASDAQ: BKYI), an innovative provider of workforce and customer identity and access management (IAM) solutions featuring Identity-Bound Biometrics (IBB) for phoneless, tokenless, passwordless and phish-resistant authentication experiences, announced that its long-time customer, the province of British Columbia, has placed new orders with BIO-key. 10,000 users will be added to their existing deploy ...

MINNEAPOLIS, Sept. 18, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today issued its 2024 Corporate Sustainability Report (CSR), detailing the continued progress advancing its Environmental, Social and Governance (ESG) initiatives. Bio-Techne's CSR is organized around four key pillars: Our People, Advancing Science, Governance and Operational Integrity, and The Environment. Bio-Techne's EPIC values (Empowerment, Passion, Innovation and Collaboration) remain the backbone of our corporate cultur ...

HOLMDEL, N.J., Sept. 12, 2024 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (NASDAQ: BKYI), an innovative provider of workforce and customer identity and access management (IAM) solutions featuring Identity-Bound Biometrics (IBB) for phoneless, tokenless, passwordless and phish-resistant authentication experiences, today announced it has entered into a warrant inducement agreement with an existing institutional investor for the immediate exercise of certain outstanding warrants that the Company issued on ...

Core Insights - BIO-key International, Inc. has received over $500K in new orders from a respected government defense ministry for its biometric user authentication solution under a three-year purchasing agreement [1][2][4] - The defense ministry is expanding the deployment of BIO-key's solution to over 33,000 users, indicating a growing interest in biometric authentication within the defense sector [2][4] - BIO-key's platform has been integrated with the ministry's virtual desktop infrastructure, allowing secure biometric authentication without the need for phones or tokens [3][4] Company Overview - BIO-key specializes in identity and access management (IAM) solutions that utilize Identity-Bound Biometrics (IBB) for secure, phoneless, tokenless, and passwordless authentication [1][4] - The company has a history of providing secure solutions across various highly-regulated industries, including government, defense, finance, and retail [4] - BIO-key's IAM software secures access for over 35 million users, offering a range of authentication factors tailored to diverse use cases [4]

MINNEAPOLIS, Aug. 26, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer will present at the following investor conferences: Morgan Stanley 22nd Annual Global Healthcare Conference September 4, 2024 4:05 PM EDT 2024 Wells Fargo Healthcare Conference September 6, 2024 11:00 AM EDT Baird 2024 Global Healthcare Conference September 10, 2024 1:25 PM EDT A live webcast of the presentations can be accessed via the IR Calendar page o ...

HOLMDEL, N.J., Aug. 22, 2024 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (NASDAQ: BKYI), an innovative provider of workforce and customer Identity and Access Management (IAM) software featuring passwordless, phoneless and token-less Identity-Bound Biometrics (IBB) authentication solutions, will participate at H.C. Wainwright's 26th Annual Hybrid Global Investment Conference September 9th and 10th. BIO-key's CEO Mike DePasquale will be available for virtual meetings on Monday and Tuesday, September 9th ...

Bio-Rad Laboratories, Inc. (BIO) is gaining investors' confidence due to its Digital PCR business, which boasts a strong pipeline. The company's Clinical Diagnostics arm is seeing increased demand for quality control, blood typing and diabetes products. Sound financial stability also appears encouraging. However, pricing pressure due to tough competition, along with adverse macroeconomic impacts, might deter Bio-Rad's growth. Persistent reduced demand in the Biopharma segment adds to the worry. Year to date ...

HOLMDEL, N.J. , Aug. 15, 2024 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (NASDAQ: BKYI), an innovative provider of workforce and customer Identity and Access Management (IAM) software featuring passwordless, phoneless and token-less Identity-Bound Biometrics (IBB) authentication solutions, announced the availability of its PortalGuard IDaaS platform in the Amazon Web Services (AWS) Marketplace enabling AWS customers around the world to seamlessly purchase and integrate PortalGuard and its IBB authenti ...